Risk: Benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus

Expert Opinion on Drug Safety

Volumn 3, Issue 4, 2004, Pages 273-278

  Horizon, Arash A ^a   Wallace, Daniel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclooxygenase (COX) 2 inhibitors; Efficacy; NSAIDs; Pregnancy; Systemic lupus erythematosus (SLE); Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CELECOXIB; CORTICOSTEROID; DICLOFENAC; ETODOLAC; FENOPROFEN; HISTAMINE H2 RECEPTOR; IBUPROFEN; INDOMETACIN; LOOP DIURETIC AGENT; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; ROFECOXIB; SULFONAMIDE; SULINDAC; THIAZIDE DIURETIC AGENT; TOLMETIN; UNINDEXED DRUG; WARFARIN;

ACUTE KIDNEY FAILURE; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ARTHRITIS; ASEPTIC MENINGITIS; BRONCHOSPASM; BULLOUS SKIN DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DRUG BINDING; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG MONITORING; DRUG SAFETY; DRUG SELECTIVITY; ERYTHEMA MULTIFORME; FEVER; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; INFLAMMATION; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE NECROSIS; LIVER TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL LITERATURE; NEPHROTOXICITY; PATIENT MONITORING; PHOTOSENSITIVITY DISORDER; PRESCRIPTION; RASH; REVIEW; RIGIDITY; RISK BENEFIT ANALYSIS; RISK FACTOR; SODIUM RETENTION; SPONTANEOUS ABORTION; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA;

ABORTION, SPONTANEOUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; EXANTHEMA; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENINGITIS, ASEPTIC; PREGNANCY; RISK ASSESSMENT;

EID: 3543116596     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.4.273     Document Type: Review

References (59)

1. GARCIA L: Pain - free at last. Dallas Morning News. September 6 (1996):1C.
2. HAWKEY CJ: Cox-2 inhibitors. Lancet (1999) 359:307-314.
3. LIPSKY PE, BROOKS P, CROFFORD LJ et al.: Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and diseases. Arch. Intern. Med. (2000) 160(7):913-920.
4. BJARNASON I, MACPHERSON A, ROTMAN H et al.: A randomized, double-blind, crossover compared with endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand. J. Gastroenterol. (1997) 32(2):126-130.
5. SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of Celecoxib in rheumatoid arthritis: a randomized controlled study. JAMA (1999) 282(20):1921-1928.
6. LANGHOF H: Target therapy of the vascular injury in subacute lupus erythematosus with irgapyrin. Dermatol, Wochenschr. (1953) 128:877-884.
7. HARVEY AM, SHULMAN LE, TUMULTY AP et al.: Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (1954) 33:291-437.
8. DUBOIS EL: Systemic lupus erythematosus: recent advances in its diagnosis and treatment. Ann. Intern. Med. (1956) 45:163-184.
9. DUBOIS EL: Management of systemic lupus erythematosus. Mod. Treat. Med. (1975) 3:1245-1249.
10. DUBOIS EL: Letter: Ibuprofen for systemic lupus erythematosus. N. Engl. J. Med. (1975) 15:779.
11. KARSH J, KIMBERLY RP, STAHL NI et al.: Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus. Arthritis Rheum. (1980) 23(12):1401-1404.
12. WALLACE DJ, METZGER AL, KLINENBERG JR: NSAID usage patterns by rheumatologists in the treatment of SLE. J. Rheumatol. (1989) 16(4):557-560.
13. RAMSAY-GOLDMAN R, MIENTUS JM, MEDSGER TA: Toxicity of nonsteroidal anti-inflammatory drugs in patients with system lupus erythematosus. Arthritis Rheum. (1989) 32:S75.
14. GERGELY P: Treatment of system lupus erythematosus (SLE) with piroxicam (Hotemin-Egis). Ther. Hung. (1989) 37:83-85.
15. ESPINOZA LR, JARA LJ, MARTINEZ-OSUNA P et al.: Refractory nephritic syndrome in lupus nephritis: favorable response to indomethacin therapy. Lupus (1993) 2(1):9-14.
16. LANDERS, WALLACE DJ, WEISMAN M: Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus (2002) 11:340-347.
17. BUCKALEW VJ: Nonsteroidal anti-inflammatory drugs in the kidney. In: Primer in Kidney Disease. Academic Press, San Diego, USA (1998):291-298.
18. CLEMENTS P, PAULUS H: Salicylates and nonsteroidal therapy In: Dubois' Lupus Erythematosus. Williams & Wilkins, Baltimore (1997):1109-1116.
19. KIMBERLY RP, PLOTZ PH: Aspirin-induced depression of renal function. N. Engl. J. Med. (1977) 296(8):418-424.
20. HERRARA-ACOSTA J: La inhibicion de la sintesis de prostagladinas suprime la reserve functional renal en pacientes con nefropatia lupica. Rev. Invest. Clin. (1987) 39(2):107-114.
21. NAGAYAMA Y: Beneficial effect of prostaglandin E1 in three cases of lupus nephritis with nephritic syndrome. Ann. Allergy. (1988) 61(2):289-295.
22. PATRONO C, PATRIGNANI P, GARCIA RODRIGUEZ LA: Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J. Clin. Invest. (1985) 76(3):1011-1018.
23. LING BN, BERNSTEIN KE, MARRERO MB: Naproxen-induced nephropathy in systemic lupus erythematosus. Nephron (1990) 54(3):249-255.
24. BREZIN JH: Reversible renal failure and nephritic syndrome associated with nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1979) 301(23):1271-1273.
25. NO AUTHORS LISTED: Renal effects of fenoprofen. Ann. Intern. Med. (1980) 93(3):508-509.
26. WOLFE MM, LICHTENSIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340(24):1888-1899.
27. EHSANULLAH RS, PAGE MC, TILDESLEY G et al.: Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. Br. Med. J. (1988) 297:1017-1021.
28. ROBINSON MG, GRIFFIN JW, BOWERS J et al.: Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig. Dis. Sci. (1989) 34(3):424-428.
29. LANZA FL: A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol. (1998) 93(11):2037-2046.
30. ROTH SH, TINDALL EA, JAIN AK et al.: A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch. Intern. Med. (1993) 153(22):2565-2571.
31. LANGMAN MJ, JENSEN DM, WATSON DJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA (1999) 282(20):1929-1933.
32. MIZUNO H, SAKAMOTO C, MATSUDA K et al.: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology (1997) 112(2):387-397.
33. SCHMASSMANN A, PESKAR BM, STETTLER C et al: Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br. J. Pharmacol. (1998) 123(5):795-804.
34. WIDENER HL, LITTMAN BH: Ibuprofen-induced meningitis in system lupus erythematosus. JAMA (1978) 239(11):1062-1064.
35. MORIS G, GARCIA-MONCO JC: The challenge of drug-induced aseptic meningitis. Arch. Intern. Med. (1999) 159(11):1185-1194.
36. WASNER CK: Ibuprofen, meningitis, and systemic lupus erythematosus. J. Rheumatol. (1978) 5(2):162-164.
37. SAMUELSON CO, WILLIAMS HJ: lbuprofen-associated aseptic meningitis in systemic lupus erythematosus. West. J. Med. (1979) 131(1):57-59.
38. BERLINER S, WEINBERGER A, SHOENFELD Y et al.: Ibuprofen may induce meningitis in (NZB × NZW)F1 mice. Arthritis Rheum. (1985) 28(1):104-107.
39. RUPPERT GB, BARTH WF: Tolmetin-induced aseptic meningitis. JAMA (1981) 245(1):67-68.
40. WEKSLER BB, LEHANY AM: Naproxen-induced recurrent aseptic meningitis. DICP (1991) 25(11):1183-1184.
41. BALLAS ZK, DONTA ST: Sulindac-induced aseptic meningitis. Arch. Intern. Med. (1982) 142(1):165-166.
42. SHOENFELD Y, LIVNI E, SHAKLAI M et al.: Sensitization to ibuprofen in systemic lupus erythematosus. JAMA (1980) 244(6):547-548.
43. NO AUTHORS LISTED: Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology (1993) 186(3):164-169.
44. SZCZEKLIK A, GRYGLEWSKI RJ, CZERNIAWSKA-MYSIK G: Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J. Allergy Clin. Immunol. (1977) 60(5):276-284.
45. BIGBY M, STERN R: Cutaneous reactions to nonsteroidal anti-inflammatory drugs. A review. J. Am. Acad. Dermatol. (1985) 12(5):866-876.
46. PETRI M, ALLBRITTON J: Antibiotic allergy in systemic lupus erythematosus: a case-control study. J. Rheumatol. (1992) 19(2):265-269.
47. WANG CR, CHUANG CY, CHEN CY: Drug allergy in Chinese patients with systemic lupus erythematosus. J. Rheumatol. (1993) 20(2):399-400.
48. DESHAZO RD, KEMP SF: Allergic reactions to drugs and biologic agents. JAMA (1997) 278(22):1895-1906.
49. PATTERSON R, BELLO AE, LEFKOWITH J: Immunologic tolerability profile of celecoxib. Clin. Ther. (1999) 21(12):2065-2079.
50. CHIOLERO A, MAILLARD MP, BURNIER M: Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert Opin. Drug Saf. (2002) 1(1):45-52.
51. MEAGHER EA: Balancing gastroprotection and cardioprotection with selective cyclooxygenase 2 inhibitors: clinical implications. Drug Saf. (2003) 26(13):913-924.
52. NISHIHARA KK, FURST DE: Aspirin and other nonsteroidal anti-inflammatory drugs. In: Arthritis and allied conditions: a textbook on rheumatology. Williams & Wilkins, Baltimore (1997):611-654.
53. MAICHE AG: Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet (1986) 1(8494):1390.
54. STEWART CF: Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum. (1991) 34(12):1514-1520.
55. MACONES GA, MARDER SJ, CLOTHIER B et al.: The controversy surrounding indomethacin for tocolysis. Am. J. Obstet. Gynecol (2001) 184:264-272.
56. BARRY WS, MEINZINGER MM, HOWSE CR: Ibuprofen overdose and exposure in utero: results from a postmarketing voluntary reporting system. Am. J. Med. (1984) 77:35-39.
57. LI D, LIU L, ODOULI R: Exposure to nonsteroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br. Med. J. (2003) 327:368-372.
58. NIELSEN GL, SORENSEN HT, LARSEN H et al.: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population-based observational study and case-control study. Br. Med. J. (2001) 322:266-270.
59. NO AUTHORS LISTED: CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet (1994) 343:619-629.